Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease

Autores
Crivaro, Andrea Natalia; Mucci, Juan Marcos; Bondar, Constanza María; Ormazabal, Maximiliano Emanuel; Ceci, Romina; Simonaro, Calogera; Rozenfeld, Paula Adriana
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Gaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti-inflammatory effects in mucopolysaccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the in vitro effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated in vitro bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in in vitro models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of in vitro models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases.
Facultad de Ciencias Exactas
Instituto de Estudios Inmunológicos y Fisiopatológicos
Materia
Ciencias Exactas
Gaucher's disease
cytokines
inflammatory diseases
osteoclasts
cytokine therapy
lysosomes
osteoblasts
Fabry disease
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/107850

id SEDICI_35dc385efca9e42bc42f3961c76a882e
oai_identifier_str oai:sedici.unlp.edu.ar:10915/107850
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher DiseaseCrivaro, Andrea NataliaMucci, Juan MarcosBondar, Constanza MaríaOrmazabal, Maximiliano EmanuelCeci, RominaSimonaro, CalogeraRozenfeld, Paula AdrianaCiencias ExactasGaucher's diseasecytokinesinflammatory diseasesosteoclastscytokine therapylysosomesosteoblastsFabry diseaseGaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti-inflammatory effects in mucopolysaccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the <i>in vitro</i> effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated <i>in vitro</i> bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in <i>in vitro</i> models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of <i>in vitro</i> models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases.Facultad de Ciencias ExactasInstituto de Estudios Inmunológicos y Fisiopatológicos2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/107850enginfo:eu-repo/semantics/altIdentifier/url/http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6544267&blobtype=pdfinfo:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217780info:eu-repo/semantics/altIdentifier/issn/1932-6203info:eu-repo/semantics/altIdentifier/pmid/31150494info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0217780info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-10-15T11:15:46Zoai:sedici.unlp.edu.ar:10915/107850Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-10-15 11:15:46.719SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
title Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
spellingShingle Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
Crivaro, Andrea Natalia
Ciencias Exactas
Gaucher's disease
cytokines
inflammatory diseases
osteoclasts
cytokine therapy
lysosomes
osteoblasts
Fabry disease
title_short Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
title_full Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
title_fullStr Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
title_full_unstemmed Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
title_sort Efficacy of pentosan polysulfate in <i>in vitro</i> models of lysosomal storage disorders: Fabry and Gaucher Disease
dc.creator.none.fl_str_mv Crivaro, Andrea Natalia
Mucci, Juan Marcos
Bondar, Constanza María
Ormazabal, Maximiliano Emanuel
Ceci, Romina
Simonaro, Calogera
Rozenfeld, Paula Adriana
author Crivaro, Andrea Natalia
author_facet Crivaro, Andrea Natalia
Mucci, Juan Marcos
Bondar, Constanza María
Ormazabal, Maximiliano Emanuel
Ceci, Romina
Simonaro, Calogera
Rozenfeld, Paula Adriana
author_role author
author2 Mucci, Juan Marcos
Bondar, Constanza María
Ormazabal, Maximiliano Emanuel
Ceci, Romina
Simonaro, Calogera
Rozenfeld, Paula Adriana
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Exactas
Gaucher's disease
cytokines
inflammatory diseases
osteoclasts
cytokine therapy
lysosomes
osteoblasts
Fabry disease
topic Ciencias Exactas
Gaucher's disease
cytokines
inflammatory diseases
osteoclasts
cytokine therapy
lysosomes
osteoblasts
Fabry disease
dc.description.none.fl_txt_mv Gaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti-inflammatory effects in mucopolysaccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the <i>in vitro</i> effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated <i>in vitro</i> bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in <i>in vitro</i> models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of <i>in vitro</i> models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases.
Facultad de Ciencias Exactas
Instituto de Estudios Inmunológicos y Fisiopatológicos
description Gaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation is activated in those disorders, which could play a role in pathogenesis. Significant degrees of amelioration occur in patients upon introduction of specific therapies; however, restoration to complete health status is not always achieved. The idea of an adjunctive therapy that targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic sulfated polyanions that have been shown to have anti-inflammatory effects in mucopolysaccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothesized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry diseases. The objective of this work is to analyze the <i>in vitro</i> effect of PPS on inflammatory cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associated <i>in vitro</i> bone alterations. Cultures of peripheral blood mononuclear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proinflammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and conditioned media was harvested in order to analyze if those cells secrete factors that induce osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to reduce the production of proinflammatory cytokines in <i>in vitro</i> models of Fabry and Gaucher diseases. Moreover, it was effective at ameliorating bone alterations of <i>in vitro</i> models of Gaucher disease. These results serve as preclinical supportive data to start clinical trials in human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and Gaucher diseases.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/107850
url http://sedici.unlp.edu.ar/handle/10915/107850
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6544267&blobtype=pdf
info:eu-repo/semantics/altIdentifier/url/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217780
info:eu-repo/semantics/altIdentifier/issn/1932-6203
info:eu-repo/semantics/altIdentifier/pmid/31150494
info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0217780
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1846064215514677248
score 13.22299